Atlas and Novartis make seed investment

Atlas Venture and Novartis Venture Fund have completed a seed funding round with Bicycle Therapeutics, a UK biotechnology company.

Dr Regina Hodits of Atlas and Dr Anja Koenig of Novartis have joined the board of directors at the company.

It is a spin-out from the MRC Laboratory of Molecular Biology, Cambridge, and use a technology platform based on the work of founders Sir Gregory Winter, a scientific founder for both CAT and Domantis, and Dr Christian Heinis. The company is managed by CEO Dr John Tite.

Bicycle Therapeutics is working to create a new generation of biotherapeutics, which seeks to combined the best aspects of small molecules and biologics to create highly specific and highly stable drugs.